iTeos Therapeutics (NASDAQ:ITOS) Rating Lowered to Sell at Zacks Investment Research

Zacks Investment Research lowered shares of iTeos Therapeutics (NASDAQ:ITOS) from a hold rating to a sell rating in a research note published on Saturday morning, Zacks.com reports.

According to Zacks, “iTeos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery and development of immuno-oncology therapeutics. iTeos Therapeutics Inc. is based in Cambridge, United States. “

Several other analysts have also recently weighed in on ITOS. SVB Leerink lifted their price objective on shares of iTeos Therapeutics from $36.00 to $37.00 and gave the stock an outperform rating in a research note on Thursday. Wedbush began coverage on iTeos Therapeutics in a research note on Tuesday, August 18th. They issued an outperform rating and a $45.00 price target for the company. Robert W. Baird started coverage on iTeos Therapeutics in a research note on Wednesday, October 7th. They set an outperform rating and a $45.00 price objective on the stock. Piper Sandler started coverage on iTeos Therapeutics in a report on Tuesday, August 18th. They issued an overweight rating and a $50.00 price objective for the company. Finally, JPMorgan Chase & Co. began coverage on iTeos Therapeutics in a report on Tuesday, August 18th. They set an overweight rating and a $40.00 target price on the stock. One analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus target price of $43.40.

Shares of NASDAQ ITOS opened at $25.40 on Friday. The business’s 50 day moving average price is $23.54. iTeos Therapeutics has a 1-year low of $17.50 and a 1-year high of $34.33.

iTeos Therapeutics (NASDAQ:ITOS) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.11). On average, research analysts expect that iTeos Therapeutics will post -2.34 EPS for the current year.

Several institutional investors have recently bought and sold shares of ITOS. Morgan Stanley bought a new stake in shares of iTeos Therapeutics during the 3rd quarter worth $59,000. JPMorgan Chase & Co. bought a new position in shares of iTeos Therapeutics in the third quarter worth about $96,000. SG Americas Securities LLC acquired a new stake in shares of iTeos Therapeutics in the 3rd quarter valued at approximately $112,000. New York State Common Retirement Fund bought a new stake in shares of iTeos Therapeutics during the 3rd quarter valued at approximately $121,000. Finally, California State Teachers Retirement System bought a new stake in shares of iTeos Therapeutics during the 3rd quarter valued at approximately $399,000.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for cancer patients. Its product pipeline includes EOS-850, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial.

See Also: The mechanics of the bid-ask spread in trading

Get a free copy of the Zacks research report on iTeos Therapeutics (ITOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for iTeos Therapeutics (NASDAQ:ITOS)

Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.